自免疾病IL-17赛道:单抗领跑,小分子“折戟”,环肽能否破局?

摩熵医药
Dec 25, 2025

在自免疾病领域,IL-17作为成熟靶点,研发竞争日趋激烈,渐成红海,其激烈程度堪比PD-1。目前,靶向IL-17的药物仍以单抗为主,全球已有7款IL17单抗药物获批上市,多款生物类似药“扎堆III期”;尚无IL-17小分子药物获批上市,但是慢病治疗领域,由“针头”转向“药丸”的趋势,开发IL-17小分子抑制剂正是行业寻求差异化竞争的新策略。但是在IL-17的“靶点红海”中,小分子抑制剂是否还有竞争...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10